CTHRepealedLegislation
National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011 (No. PB 81 of 2011)
6Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%
Start here
Get a plain-English read of 6
Turn the raw legal text into a practical explanation grounded in National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011 (No. PB 81 of 2011).
6 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.